Live Terminal
Telegram

CEO turned informant: How the FDA built a case against executives promising cheap medications

Share on WhatsApp Telegram
⚡ Instant Key Takeaways (TL;DR)
🎯
Core Development: CEO turned informant: How the FDA built a case against executives promising cheap medications
📊
Market & Financial Impact: The FDA's unprecedented criminal case against an alternative funding program hinged on the cooperation of a peer CEO, according to a court record.
💡
Actionable Insight: Monitor price volume action at market open; check key technical support/resistance levels.

The federal case against an alleged illegal prescription drug operation and its two top leaders earlier this month features a notable informant: the CEO of a peer company that authorities say was committing the same import violations.

John Thomas Howard, treasurer and director of a Canadian healthcare company called CANARX, was arrested in the tunnel connecting Detroit and Canada on Nov. 8 and charged with smuggling, conspiracy and importing a misbranded drug for patient use in the United States. His brother and the president of the company, Bob Howard, is wanted on similar charges and was still being sought as of last week, according to court records.

The charges mark the first criminal case by U.S. authorities against a company that's part of a cottage industry known as alternative funding programs, or AFPs, that promise to lower or eliminate high prescription drug costs for Americans.

The cheaper medications are typically sourced from international markets, a business model that the Food and Drug Administration and Department of Homeland Security say is illegal and can put patients' health at risk.

At issue is the unregulated nature of drugs intended for foreign markets and, in some cases, the risk of counterfeit products. And while AFPs generally argue that the importation of medication is allowable under U.S. law by individuals for personal use, authorities contend the operations go too far.

📰
Official Publisher Attribution: This report is aggregated from CNBC. ZeroLive provides live aggregation, automated sentiment synthesis, and exchange disclosure monitoring for retail market participants.
Read Original Full Coverage on CNBC ↗
⚡
Get Breaking Stock Alerts & Q-Results on Telegram
Real-time 1200x675 image cards and financial filings delivered instantly.
Join @Zerolive_news ↗
Link copied to clipboard! ✅